Claims
1. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,
O R30R40
\ // N ^< 60 I
D-E H R750 R
wherein
A is chosen from the series consisting of C(R1) and N;
D is chosen from the series consisting of N(R2), O and S;
E is chosen from the series consisting of C(R3) and N;
G is chosen from the series consisting of R71-0-C(0)-, R72-N(R73)-C(0)-, NC- and tetrazol-5-yl;
R1 is chosen from the series consisting of hydrogen, halogen, (d-C6)-alkyl, Ar, HO-, (Ci-C6)-alkyl-0-, (Ci-C6)-alkyl-S(0)m- and NC-;
R2 is chosen from the series consisting of (Ci-C7)-alkyl, (C3-C7)-cycloalkyl-CsH2s- and Ar-CsH2s-, wherein s is an integer chosen from the series consisting of 0, 1,2 and 3;
R3 is chosen from the series consisting of hydrogen, halogen, (d-C6)-alkyl, (C1-C6)-alkyl-O-, (Ci-C6)-alkyl-S(0)m- and NC-;
R10 is chosen from the series consisting of R11-0-, R12-N(R13)-C(0)-0- and Het2-C(0)-0-;

R11 is chosen from the series consisting of hydrogen, R14, (C3-C7)-cycloalkyl, Ar and Het3;
R12 and R13 are independently of each other chosen from the series consisting of hydrogen, R15 and Ar;
R14 is (d-Cio)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, R16-0-, oxo, (C3-C7)-cycloalkyl, Ar, Het1, Het3, NC-, H2N-C(0)-, (CrC4)-alkyl-NH-C(0)-, di((d-C4)-alkyl)N-C(O)-, Het1-C(0)-, (CrC4)-alkyl-C(0)-NH-and (CrC4)-alkyl-S(0)m-;
R15 is (Ci-Ce)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting halogen, HO- and (Ci-Ce)-alkyl-O-;
R16 is (Ci-Ce)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of HO-, (d-C4)-alkyl-0- and NC-;
R30 is chosen from the series consisting of R31, (C3-C7)-cycloalkyl, R32-CuH2u- and Het3-CuH2u-, wherein u is an integer chosen from the series consisting of 0, 1,2 and 3;
R31 is (d-Cio)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C3-C7)-cycloalkyl, HO-, (d-C6)-alkyl-0-, (CrC6)-alkyl-S(0)m- and NO;
R32 is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (d-C6)-alkyl, (C3-C7)-cycloalkyl, R33, HO-, (C1-C6)-alkyl-O-, R33-0-, R33-(d-C4)-alkyl-0-, -0-CH2-0-, -0-CF2-0-, (CrC6)-alkyl-S(0)m-, H2N-S(0)2-, (CrC4)-alkyl-NH-S(0)2-, di((CrC4)-alkyl)N-S(0)2-, H2N-, (CrC6)-alkyl-NH-

, di((CrC6)-alkyl)N-, Het1, (CrC4)-alkyl-C(0)-NH-, Ar-C(0)-NH-, (CrC4)-alkyl-S(0)2-NH- and NC-;
R33 is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (d-C6)-alkyl, (C3-C7)-cycloalkyl, HO-, (Ci-Ce)-alkyl-O-
, (CrC6)-alkyl-S(0)m-, H2N-S(0)2-, (Ci-C4)-alkyl-NH-S(0)2-, di((CrC4)-alkyl)N-S(0)2-and NC-;
R40 is chosen from the series consisting of hydrogen and (d-C4)-alkyl;
or R30 and R40 together are (CH2)X which is optionally substituted by one or more identical or different (d-C4)-alkyl substituents, wherein x is an integer chosen from the series consisting of 2, 3, 4 and 5;
R50 is chosen from the series consisting of hydrogen, (d-C6)-alkyl, HO- and (CrCe)-alkyl-O-;
R60 is chosen from the series consisting of hydrogen and (Ci-Ce)-alkyl;
or R50 and R60 together are (CH2)y which is optionally substituted by one or more identical or different (d-C4)-alkyl substituents, wherein y is an integer chosen from the series consisting of 2, 3, 4 and 5;
R71 is chosen from the series consisting of hydrogen and (Ci-CsJ-alkyI which is optionally substituted by one or more identical or different substituents chosen from the series consisting (Ci-Ce)-alkyl-O- and (d-C6)-alkyl-C(0)-0-;

R72 is chosen from the series consisting of hydrogen, (Ci-Ce)-alkyl, (C3-C6)-cycloalkyl,
-CH2-(CH2)b-(C3-C6)-cycloalkyl, Het4 and -(CH2)b-Het4, where alkyl or cycloalkyl is
optionally substituted by one or more identical or different substituents chosen from the
series consisting of halogen, HO-, HOOC-, (d-C6)-alkyl-0- and (CrC6)-alkyl-C(0)-0-,
NC-, N((Ci-C4)-alkyl)2 and b is 0, 1 or 2;
R73 is chosen from the series consisting of hydrogen, (Ci-Ce)-alkyl;
or
R72 and R73 together with the nitrogen atom to which they are bonded form a saturated
4-membered to 7-membered monocyclic heterocycle, which contain optionally one
further ring heteroatom chosen from the series consisting of nitrogen, oxygen and
sulfur, which is optionally substituted by one or more identical or different substituents
chosen from the series consisting of halogen, (Ci-C4)-alkyl, HO- and (Ci-C4)-alkyl-0-;
Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C1-C6)-alkyl, (CrC6)-alkyl-0-, -0-CH2-0-, -0-CF2-0-, (CrC6)-alkyl-S(0)m-, H2N-S(0)2- and NC-;
Het1, independently of each other group Het1, is a saturated or unsaturated 4-membered to 8-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het1 is bonded and optionally one or two identical or different further ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C4)-alkyl, HO-, (d-C4)-alkyl-0-, oxo and NC-
■
Het2 is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het2 is bonded and optionally one further ring

heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C4)-alkyl, HO- and (Ci-C4)-alkyl-0-;
Het3, independently of each other group Het3, is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises one or two identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine, (C1-C4)-alkyl and oxo;
Het4, independently of each other group Het4, is a saturated or unsaturated 4-membered to 8-membered monocyclic heterocycle which comprises one to four ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C4)-alkyl, HO-, (d-C4)-alkyl-0-, oxo and NC-;
m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2;
wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (Ci-C4)-alkyl;
wherein all alkyl, CsH2s, CuH2u, (CH2)X and (CH2)y groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents.
2. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 1, wherein E is N.

3. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 and 2, wherein D is N(R2).
4. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 3, wherein
A is chosen from the series consisting of C(R1) and N;
D is N(R2);
EisN;
R1 is chosen from the series consisting of hydrogen, halogen and (Ci-C4)-alkyl;
R2 is Ar-CsH2s-, wherein s is an integer chosen from the series consisting of 0, 1 and 2.
5. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 4, wherein R10 is R11-0-.
6. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 5, wherein R30 is R32-CuH2u- wherein u is an integer chosen from the series consisting of 0 and 1.
7. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 6, wherein
G is chosen from the series consisting of R71-0-C(0)- and R72-N(R73)-C(0)-;

R30 is R32-CuH2u-, wherein u is an integer chosen from the series consisting of 0 and 1;
R32 is chosen from the series consisting of phenyl and an aromatic 6-membered
monocyclic heterocycle which comprises one or two nitrogen atoms as ring
heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by
one, two or three identical or different substituents chosen from the series consisting of
halogen, (CrC6)-alkyl, (C3-C7)-cycloalkyl, R33, (CrC6)-alkyl-0-, R33-0-, R33-(Ci-C4)-
alkyl-O-, -O-CH2-O-, -O-CF2-O-, (CrC6)-alkyl-S(0)m-, (CrC6)-alkyl-NH-, di((Ci-C6)-
alkyl)N-, Het1 and NC-;
R33 is chosen from the series consisting of phenyl and pyridinyl which all are optionally
substituted by one, two or three identical or different substituents chosen from the
series consisting of halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyl-0-, (CrC4)-alkyl-S(0)m- and
NC-;
R40 is hydrogen;
R50 is hydrogen;
R60 is hydrogen.
8. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 7, wherein
A is chosen from the series consisting of C(R1) and N;
D is N(R2);
E is chosen from the series consisting of C(R3) and N;
G is chosen from the series consisting of R71-0-C(0)- and R72-N(R73)-C(0)-;
R1 is chosen from the series consisting of hydrogen, halogen, (d-C6)-alkyl, HO- and (CrC6)-alkyl-0-;

R2 is chosen from the series consisting of (Ci-C7)-alkyl, (C3-C7)-cycloalkyl-CsH2s- and Ar-CsH2s-, wherein s is an integer chosen from the series consisting of 0, 1,2 and 3;
R3 is chosen from the series consisting of hydrogen, halogen, (Ci-Ce)-alkyl and (Ci-C6)-alkyl-0-;
R10 is chosen from the series consisting of R11-0-, R12-N(R13)-C(0)-0- and Het2-C(0)-0-;
R11 is chosen from the series consisting of hydrogen, R14, (C3-C7)-cycloalkyl and Het3;
R12 and R13 are independently of each other chosen from the series consisting of hydrogen, R15 and Ar;
R14 is (d-Cio)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, R16-0-, oxo, (C3-C7)-cycloalkyl, Ar, Het1, Het3, NC-, H2N-C(0)-, (CrC4)-alkyl-NH-C(0)-, di((Ci-C4)-alkyl)N-C(O)- and Het1-C(0)-;
R15 is (CrC6)-alkyl;
R16 is (Ci-Ce)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of HO- and (Ci-C4)-alkyl-0-;
R30 is chosen from the series consisting of (C3-C7)-cycloalkyl, R32-CuH2u- and Het3-CuH2u-, wherein u is an integer chosen from the series consisting of 0, 1,2 and 3;
R32 is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (CrC6)-alkyl, (C3-C7)-cycloalkyl, R33, HO-, (CrC6)-alkyl-0-, R33-0-, R33-(d-

C4)-alkyl-0-, -0-CH2-0-, -0-CF2-0-, (CrC6)-alkyl-S(0)m-, di((Ci-C4)-alkyl)N-S(0)2-, H2N-, di((CrC6)-alkyl)N-, Het1, (CrC4)-alkyl-C(0)-NH-, Ar-C(0)-NH- and NC-;
R33 is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (CrC6)-alkyl, (C3-C7)-cycloalkyl, HO-, (CrC6)-alkyl-0-, (Ci-C6)-alkyl-S(0)m-, H2N-S(0)2-, di((CrC4)-alkyl)N-S(0)2- and NC-;
R40 is hydrogen;
R50 is chosen from the series consisting of hydrogen and HO-;
R60 is hydrogen;
R71 is chosen from the series consisting of hydrogen and (Ci-CsJ-alkyI which is optionally substituted by one or more identical or different substituents chosen from the series consisting (Ci-Ce)-alkyl-O- and (d-C6)-alkyl-C(0)-0-;
R72 and R73 are independently of each other chosen from the series consisting of hydrogen and (d-C4)-alkyl;
Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (CrCe)-alkyl, (CrC6)-alkyl-0-, -0-CH2-0-, -0-CF2-0-, (CrC6)-alkyl-S(0)m- and NC-;

Het1, independently of each other group Het1, is a saturated or unsaturated 4-membered to 8-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het1 is bonded and optionally one or two identical or different further ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C4)-alkyl, HO-, (Ci-C4)-alkyl-0-, oxo and NC-
■
Het2 is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het2 is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C4)-alkyl, HO- and (d-C4)-alkyl-0-;
Het3, independently of each other group Het3, is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises one or two identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine, (C1-C4)-alkyl and oxo;
m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2;
wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (d-C4)-alkyl;
wherein all alkyl, CsH2s, CuH2u, (CH2)X and (CH2)y groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents;

9. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 8, wherein
AisC(R1);
D is N(R2);
EisN;
G is chosen from the series consisting of R71-0-C(0)- and R72-N(R73)-C(0)-;
R1 is chosen from the series consisting of hydrogen, halogen and (Ci-C4)-alkyl;
R2 is Ar-CsH2s-, wherein s is 0;
R10isR11-O-;
R11 is chosen from the series consisting of hydrogen and R14;
R14 is (d-Cio)-alkyl which is optionally substituted by one, two or three identical or different substituents chosen from the series consisting of HO-, R16-0-, oxo, (C3-C7)-cycloalkyl, Ar, Het1, di((Ci-C4)-alkyl)N- and Het1-C(0)-;
R16 is (Ci-Ce)-alkyl which is optionally substituted by one or two identical or different substituents chosen from the series consisting of HO- and (Ci-C4)-alkyl-0-;
R30 is R32-CuH2u-, wherein u is an integer chosen from the series consisting of 0 and 1;
R32 is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring

heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one, two or three identical or different substituents chosen from the series consisting of halogen, (CrC6)-alkyl, (C3-C7)-cycloalkyl, R33, (CrC6)-alkyl-0-, R33-0-, R33-(Ci-C4)-alkyl-O-, -O-CH2-O-, -O-CF2-O-, (CrC6)-alkyl-S(0)m-, di((Ci-C6)-alkyl)N-, Het1 and NC-
■
R33 is chosen from the series consisting of phenyl and pyridinyl which all are optionally substituted by one, two or three identical or different substituents chosen from the series consisting of halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyl-0-, (CrC4)-alkyl-S(0)m- and NC-;
R40 is hydrogen;
R50 is hydrogen;
R60 is hydrogen;
R71 is chosen from the series consisting of hydrogen and (Ci-CsJ-alkyI which is optionally substituted by one substituent chosen from the series consisting (C1-C6)-alkyl-O- and (CrC6)-alkyl-C(0)-0-;
R72 and R73 are independently of each other chosen from the series consisting of hydrogen and (d-C2)-alkyl;
Ar is chosen from the series consisting of phenyl and an aromatic 6-membered heterocycle which comprises one or two nitrogen atoms as ring heteroatoms, wherein the phenyl and the heterocycle are all optionally substituted by one, two or three identical or different substituents chosen from the series consisting of halogen, (C1-C6)-alkyl, (CrC6)-alkyl-0-, (CrC6)-alkyl-S(0)m- and NC-;
Het1, independently of each other group Het1, is a saturated or unsaturated 4-membered to 6-membered monocyclic heterocycle which comprises a ring nitrogen

atom via which Het1 is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one, two or three identical or different substituents chosen from the series consisting of fluorine, (Ci-C4)-alkyl, HO- and oxo;
m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2;
wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (Ci-C4)-alkyl;
wherein all alkyl, CsH2s and CuH2u groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents.
10. A compound of the formula I, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 9, chosen from
3-[(5-Hydroxy-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-3-(4-methoxy-phenyl)-propionic acid,
3-(3-tert-Butoxy-phenyl)-3-{[1-(2,5-dimethyl-phenyl)-5-hydroxy-1H-pyrazole-3-carbonyl]-amino}-propionic acid,
(S)-3-{[1-(2-Fluoro-phenyl)-5-methoxy-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,
3-(3-Fluoro-2-methyl-phenyl)-3-{[1-(4-fluoro-phenyl)-5-hydroxy-1H-pyrazole-3-carbonyl]-amino}-propionic acid,
3-(2-Chloro-5-fluoro-phenyl)-3-{[1-(4-fluoro-phenyl)-5-hydroxy-1H-pyrazole-3-carbonyl]-amino}-propionic acid,
(S)-3-[(5-Methoxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid, 3-[(5-Hydroxy-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-3-(2-methoxy-5-trifluoromethyl-phenyl)-propionic acid,

3-(2-Fluoro-4-methyl-phenyl)-3-[(5-hydro^ propionic acid,
3-{[1-(2-Chloro-phenyl)-5-hydroxy-1H^ biphenyl-4-yl)-propionic acid, 3-[(5-Methoxy-1-phenyl-1 H-pyrazole^
propionic acid,
3-{[1-(2-Fluoro-phenyl)-5-hydroxy-1H-pyrazole-3-carbonyl]-amino}-3-(4-methanesulfonyl-phenyl)-propionic acid, (S)-3-{[5-Hydroxy-1-(2-methanesulfonyl-p^
tolyl-propionic acid, 3-{[1-(2-Fluoro-phenyl)-5-methoxy-1H-pyrazole-3-carbonyl]-amino}-3-(4-methoxy-2^
methyl-phenyl)-propionic acid, (S)-3-{[1-(2-Fluoro-phenyl)-5-methoxy-1H-pyrazole-3-carbonyl]-amino}-3-(2-
trifluoromethyl-phenyl)-propionic acid, 3-(2,3-Dimethyl-phenyl)-3-{[1-(2^ amino}-propionic acid, 3-{[5-Cyclopropylmethoxy-1-(2-fluoro-^^ fluoro-2-methyl-phenyl)-propionic acid, (S)-3-{[5-Cyclopropylmethoxy-1-(2^ m-tolyl-propionic acid,
(S)-3-{[1-(2-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazole carbonyl]-amino}-3-o-tolyl-propionic acid,
(S)-3-{[1-(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1H-pyrazo^ carbonyl]-amino}-3-o-tolyl-propionic acid,
(S)-3-{[5-(3,3-Dimethyl-2-oxo amino}-3-o-tolyl-propionic acid,
(S)-3-(2,4-Dichloro-phenyl)-3-{[1-(2-fluoro-phenyl)-5-(2-hydroxy-2-methyl^ 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,
(S)-3-{[5-(2-Cyclopropyl-2-hydroxy-propoxy)-1-(2-fluoro-phenyl)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,
(S)-3-{[1-(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,34rimethyl-butoxy)-1H-pyra^ carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1-(2-Fluoro-phenyl^
carbonyl]-amino}-3-o-tolyl-propionic acid,
(S)-3-(2-Chloro-phenyl)-3-{[1-(2-fluoro-phenyl)-5-((R)-2-hydroxy-2^
butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,
(S)-3-(2-Chloro-phenyl)-3-{[1-(2-fluoro-phenyl)-5-((S)-2-hydroxy
butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,
(S)-3-(2,4-Dichloro-phenyl)-3-{[5-(2-ethyl-2-hydroxy-butoxy)-1-(2-fluoro-^
pyrazole-3-carbonyl]-amino}-propionic acid,
(S)-3-{[1-(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1H-pyrazo^
carbonyl]-amino}-3-o-tolyl-propionic acid,
(S)-3-{[1-(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1H-pyrazol^
carbonyl]-amino}-3-o-tolyl-propionic acid,
(S)-3-(2-Chloro-phenyl)-3-{[1-(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3
1 H-pyrazole-3-carbonyl]-amino}-propionic acid,
(S)-3-(2-Chloro-phenyl)-3-{[1-(2-fluoro-phenyl)-5-((S)-2-hydroxy-3^
1 H-pyrazole-3-carbonyl]-amino}-propionic acid,
(S)-3-{[1-(2-Fluoro-phenyl)-5-((R)-2-hydro^^
carbonyl]-amino}-3-p-tolyl-propionic acid,
(S)-3-{[1-(2-Fluoro-phenyl)^
carbonyl]-amino}-3-p-tolyl-propionic acid,
(S)-3-{[5-((R)-2-Hydroxy-3,3-dimethyl-butoxy)-1-phenyl-1H-pyrazole-3-carbonyl^
amino}-3-phenyl-propionic acid,
(S)-3-{[5-((S)-2-Hydroxy-3,3-dimethyl-butoxy)-1-phenyl-1H-pyrazole-3-carbon
amino}-3-phenyl-propionic acid,
(S)-3-{[1-(2-Chloro-phenyl)-5-((R)-2^
carbonyl]-amino}-3-phenyl-propionic acid, and
(S)-3-{[1-(2-Chloro-phenyl)-5-((S)-2-hy^
carbonyl]-amino}-3-phenyl-propionic acid.
11. A process for the preparation of a compound of the formula I or a physiologically acceptable salt thereof or a physiologically solvate of any of them as claimed in any

one or more of claims 1 to 10, comprising reacting a compound of the formula II with a compound of the formula III,
O R30 R4o
O R30R40 10 A II V Q
\ II J N /\D6o D-E H Jso R
D—E H pjsoR n
II III I
wherein the groups A, D, E, G, R10, R30, R40, R50 and R60 in the compounds of the formulae II and III are defined as in the compounds of the formula I and additionally functional groups can be present in protected form or in the form of a precursor group, and the group J in the compound of the formula II is HO-, (Ci-C4)-alkyl-0- or halogen.
12. A compound of the formula I as claimed in any one or more of claims 1 to 10 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them for use as a pharmaceutical.
13. A pharmaceutical composition, which comprises at least one compound of the formula I as claimed in any one or more of claims 1 to 10 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them and a pharmaceutical^ acceptable carrier.
14. Use of a compound of the formula I as claimed in anyone or more of claims 1 to 10 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them for the manufacture of a medicament for the treatment of heart failure, congestive heart failure, cardiomyopathy, myocardial infarction, left ventricular dysfunction, cardiac hypertrophy, valvular heart diseases, hypertension, atherosclerosis, peripheral arterial occlusive disease, restenosis, vasvular permeability disorders, treatment of edema, thrombosis, rheumatoid arthritis, osteoarthritis, renal failure, cystic fibrosis, chronic bronchitis, chronic obstructive pulmonary disease, asthma, immunological diseases, diabetic complications, fibrotic diseases, pain,

ischemia or reperfusion damage or neurodegenerative diseases, or for cardioprotection or renoprotection or as a diuretic (stand-alone treatment or in combination with established diuretics)